Table 3.

10-Year Clinical Outcomes Hazard Ratios for Re-Biopsy Positive Patients [95% Confidence Interval] by Patient Subset; Referenced to Re-Biopsy Negative Patients.

	Biochemical Failure	Distant Metastases	Disease-Specific Survival	Overall Survival
Stage T1	1.62 [1.14–2.28]	2.88 [1.18–7.03]	1.92 [0.45–8.04]	1.13 [0.74–1.73]
Stage T2a–T2b	1.76 [1.30–2.39]	2.14 [0.98–4.71]	4.31 [1.89–9.84]	1.27 [0.91–1.78]
Gleason 2–6	1.63 [1.20–2.21]	1.11 [0.38–3.21]	2.33 [0.69–7.24]	1.06 [0.74–1.51]
Gleason 7–10	1.68 [1.18–2.39]	3.67 [1.64–8.21]	4.43 [1.84–10.7]	1.56 [1.04–2.35]
RT Alone	1.49 [1.11–2.00]	1.87 [0.84–4.16]	2.04 [0.81–5.11]	1.22 [0.85–1.75]
RT + TAS	1.66 [1.14–2.42]	3.22 [1.34–7.76]	7.57 [2.58–22.2]	1.28 [0.87–1.89]

RT – radiotherapy; TAS – total androgen suppression